Fig. 5: Dectin-1 blockade reactivates anti-tumour immunity in GC.

Tumour single-cell suspensions were divided into Isotype group (Mouse IgG1 isotype control antibody, 10 μg/mL) and anti-Dectin-1 group (Human Dectin-1 monoclonal antibody, 10 μg/mL). Each treatment group was cultured in RPMI1640 medium (Gibco) containing 10% foetal bovine serum (Gibco) for 12 h at 37 °C. a The frequency of CD80⁺, CD86⁺, and CD206⁺ cells gated by Dectin-1⁺ TAMs after isotype and anti-Dectin-1 treatment in tumour tissues of GC (n = 12). Representative flow cytometric plots (left) and quantitative data (right) are shown. b, c The frequency of LAP⁺, Arg1⁺ and IL-10⁺ cells (b), as well as TNF-α⁺, IL-12⁺ and IL-1β⁺ cells (c) gated by Dectin-1⁺ TAMs after isotype and anti-Dectin-1 treatment in tumour tissues of GC (n = 12). d, e The frequency of ICOS⁺ (d) TNF-α⁺ and IFN-γ⁺ cells gated by CD4⁺ and CD8⁺ T cells (e) after isotype and anti-Dectin-1 treatment in tumour tissues of GC (n = 10). f–h The frequency of TNF-α⁺IFN-γ⁺ cells (f), PD-1⁺TIM-3⁺ (g) and PD-1⁺LAG-3⁺ (h) cells gated by CD4⁺ and CD8⁺ T cells after isotype and anti-Dectin-1 treatment in tumour tissues of GC (n = 10). Representative flow cytometric plots (left) and quantitative data (right) are shown. Wilcoxon test. *P < 0.05, ** P < 0.01, *** P < 0.001, ns refers to not significant.